Targeting GSCs may effectively inhibit tumor progression and overcome resistance to current anti-angiogenic treatments, as evidenced by recent studies showing that selective deletion of stromal cell-derived factor 1 (SDF-1), which interacts with CXCR4 expressed on GSCs, suppresses tumor growth and extends survival in GBM models (52). Here, CXCR4 is linked to neoplasm.